Hemogenyx Pharmaceuticals Share Discussion Threads

[apotheki] 24/2/2024 09:30

dreamtwister 23 Feb '24 - 18:18 - 852 of 852 (Filtered)

[dreamtwister] 23/2/2024 18:18

Oh dear the rampers have gone into administration, or maybe climatizing for

the next Flood of shares to be added to the share registrar!

A company Statement.!

“Substantial funding will be required by the Company during the clinical trial phase and further funding will be sought by the Company prior to the commencement of the Phase I clinical trials.

[apotheki] 22/2/2024 13:05

Hemogenyx Pharmaceuticals plc (LSE:HEMO) are now preparing to move into clinical trials with the USA player Prevail Partners' strategic investment in the Company demonstrating their confidence in the CAR-T program and in the Company's ability to fully execute the upcoming clinical study.

[apotheki] 22/2/2024 12:55

Reckon that post the very recent FDA approval [phase 1] that there is likely to be a lot going on Corporately in the back ground!

[premium beeks] 22/2/2024 12:42

Nice one. He's soon disappear.Meanwhile we await news of funding or whatever deals are being agreed behind closed doors.The silence is deafening at the mo. I don't necessarily see that as a bad sign.

[apotheki] 22/2/2024 12:33

dreamtwister22 Feb '24 - 12:27 - 844 of 845 (Filtered)

[dreamtwister] 22/2/2024 09:54

A company Statement.!

“Substantial funding will be required by the Company during the clinical trial phase and further funding will be sought by the Company prior to the commencement of the Phase I clinical trials.

It is only a matter of time before the Cash cow develops Mastitis !

Unless a Collaboration with Financial Muscle Ensures the Antidote.

[apotheki] 22/2/2024 07:25

Hemogenyx Pharmaceuticals Announces Strategic Investment from Prevail Partners, LLC

· Prevail Partners, LLC to invest in Hemogenyx Pharmaceuticals.
· Prevail InfoWorks, Inc. to act as Contract Research Organization (CRO) for upcoming Phase I clinical study, expected to commence in 2023.

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that Prevail Partners, LLC ("Prevail Partners"), an investment fund, has agreed to invest in the Company through a subscription for 11,066,667 ordinary shares (the "New Ordinary Shares") at a price of US$0.075 per share (approximately £0.06) for the total sum of $830,000 (approximately £668,000).

The subscription price represents a premium of approximately 240% to the Company's closing share price on 14 September 2023, when agreement was reached as to the final terms of the investment. The agreement governing the subscription (the "Subscription Agreement") contains customary warranties from the Company and Prevail Partners. Following allotment, Prevail Partners will hold approximately 0.96% of the Company's issued share capital.

The Company's wholly owned subsidiary, Hemogenyx Pharmaceuticals LLC, has also signed a Master Service and Technology Agreement ("MSTA") with Prevail InfoWorks, Inc. ("InfoWorks"), a Philadelphia, PA based Contract Research Organization (CRO) and affiliate of Prevail Partners.

Under the terms of the MSTA, InfoWorks is to provide clinical services and technologies for the Company's upcoming Phase I study of its anti-FLT3 chimeric antigen receptor-redirected T cells ("CAR-T cells") in subjects with relapsed/refractory acute myeloid leukemia (AML). Services include clinical site coordination, project management, data management, clinical monitoring, and pharmacovigilance (safety management) services, and the use of InfoWorks' integrated real-time data analytics platform, The Single Interface®, for clinical support and real-time data analysis. The MSTA has an initial term of 40 months, and Hemogenyx Pharmaceuticals LLC has agreed an initial statement of works relating to the Phase I AML study.

The subscription funds will in large part defray the payment made by the Company for the first stage of the work being undertaken by InfoWorks under the MSTA.

Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "As we seek to bring the curative power of cell therapies to a greater number of patients suffering from otherwise incurable life-threatening diseases, we are very confident in Prevail InfoWorks' ability to coordinate our Phase I clinical trial in relapsed/refractory AML. Their operational experience and expertise will enable a smooth execution of the study, while their specialization in real-time data integration and analytics will ensure fast, reliable data access to lower our clinical risk and potentially speed up our regulatory timeline. Prevail Partners' strategic investment in the Company demonstrates their confidence in our CAR-T program and in our ability to execute the upcoming clinical study."

Mary Schaheen, President of Prevail Partners, stated: "Everyone at our fund is confident in the growth and success of Hemogenyx Pharmaceuticals as they develop CAR-T cells to target acute myeloid leukemia. Furthermore, Hemogenyx Pharmaceuticals has a seasoned management team with the expertise to accelerate the company to a significant value inflection point through the completion of its planned clinical trial."

[dreamtwister] 21/2/2024 22:07

steve as a charitable wager Dr Sandler will exercise his awarded share options.

i trust you to make a donation of your own free choice To a charity you support.

[premium beeks] 21/2/2024 21:38

I doubt anyone is short, just a few self important muppets with their drive by opinions.

[steveberyl] 21/2/2024 21:25

I think any Shorters are going to be hugely disappointed, indeed financially disappointed.

The Silence here is deafening, these pharma trials do not come cheap, on that basis, a placing is unlikely, very unlikely. I am waiting for news of a Partner or something else, a placing is out of the question, £5m to £10m is the required number so a placing is not on, for certain.

[premium beeks] 21/2/2024 21:10

Why would I want to expel the effort educating you? Nothing said on here is going to move the price, not in a news lull like now especially. I wonder why you feel the need to "educate" others?You are nothing but a troll. On to filter you go.Ciao.

[dreamtwister] 21/2/2024 21:01

educate me mr puppet also waiting for you to educate the forum ?

[premium beeks] 21/2/2024 20:55

Can you see any posts ramping this from me?Do you want answers because you don't know or are you asking for another reason?

[dreamtwister] 21/2/2024 20:52

ok smarty...please inform the Forum...how many patients will be enrolled

on the clinical trial,how many lines of treatment prior to the commencement

of the trial plus the metabolism of patients...timeframes between each phase

:the staged is yours or has Dr Sandler got his hand up your Jacksy or visa

versa you ramping puppet/Muppet.

[dreamtwister] 21/2/2024 20:25

posted for the information to new investors !

no trials "do not come free "sponsorship per patient Ks of dollars !